Of note, NPM1-mut AML showed a higher ex vivo sensitivity to Nut-3 and to the combined treatment compared with NPM1-wt cells at 48 h (Nut-3a: p = 0.020; drug combination: p = 0.040, Figure 3E). This evidence concerns the gene NPM1 and acute myeloid leukemia.